

Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment

Gareth J. Morgan¹, Faith E. Davies¹, Walter M. Gregory², Susan E. Bell², Alexander J. Szubert², Gordon Cook³, Mark T. Drayson⁴, Roger G. Owen³, Fiona M. Ross⁵, Graham H. Jackson⁶, and J. Anthony Child²

Abstract

Purpose: Medical Research Council (MRC) Myeloma IX was a phase III trial evaluating bisphosphonate and thalidomide-based therapy for newly diagnosed multiple myeloma. Results were reported previously after a median follow-up of 3.7 years (current controlled trials number: ISRCTN68454111). Survival outcomes were reanalyzed after an extended follow-up (median, 5.9 years).

Experimental Design: At first randomization, patients ($N = 1,970$) were assigned to bisphosphonate (clodronic acid or zoledronic acid) and induction therapies [cyclophosphamide–vincristine–doxorubicin–dexamethasone (CVAD) or cyclophosphamide–thalidomide–dexamethasone (CTD) followed by high-dose therapy plus autologous stem cell transplantation for younger/fitter patients (intensive pathway), and melphalan–prednisone (MP) or attenuated CTD (CTDa) for older/less fit patients (nonintensive pathway)]. At second randomization, patients were assigned to thalidomide maintenance therapy or no maintenance. Interphase FISH (iFISH) was used to analyze cytogenetics.

Results: Zoledronic acid significantly improved progression-free survival (PFS; HR, 0.89; $P = 0.02$) and overall survival (OS; HR, 0.86; $P = 0.01$) compared with clodronic acid. In the intensive pathway, CTD showed noninferior PFS and OS compared with CVAD, with a trend toward improved OS in patients with favorable cytogenetics ($P = 0.068$). In the nonintensive pathway, CTDa significantly improved PFS (HR, 0.81; $P = 0.007$) compared with MP and there was an emergent survival benefit after 18 to 24 months. Thalidomide maintenance improved PFS (HR, 1.44; $P < 0.0001$) but not OS (HR, 0.96; $P = 0.70$), and was associated with shorter OS in patients with adverse cytogenetics ($P = 0.01$).

Conclusions: Long-term follow-up is essential to identify clinically meaningful treatment effects in myeloma subgroups based on cytogenetics. *Clin Cancer Res*; 19(21); 6030–8. ©2013 AACR.

Introduction

Although substantial advances in myeloma treatment have prolonged survival times (1, 2), myeloma still remains incurable. Myeloma is also a heterogeneous disease, and an understanding of subtypes with different biologic behavior may help in identifying the best approach for individual patients. The Medical Research Council (MRC) Myeloma IX trial used a factorial design to evaluate the effects of bisphosphonate therapy and thalidomide-based regimens in the context of: (i) induction therapy for patients suitable for high-dose therapy with autologous stem cell transplantation

(HDT–ASCT), regardless of age; (b) initial therapy for older, less fit patients; and (c) maintenance therapy following either intensive (i.e., HDT–ASCT) or nonintensive treatment. Results from a median follow-up of 3.7 years have been published previously: zoledronic acid improves overall survival (OS) compared with clodronic acid (3); preHDT–ASCT induction therapy with CTD (cyclophosphamide–thalidomide–dexamethasone) improves response rates and is associated with noninferior progression-free survival (PFS) and OS compared with CVAD (cyclophosphamide–vincristine–doxorubicin–dexamethasone; ref. 4); use of an attenuated CTD regimen (CTDa) in patients ineligible for HDT–ASCT is associated with significantly better response, although there was no difference in OS when compared with standard melphalan–prednisone (MP; ref. 5); and thalidomide maintenance therapy improves PFS but not OS, with the benefit being seen in those with favorable interphase FISH (iFISH) cytogenetic profiles (6). The current analysis reports data from MRC Myeloma IX following an extended follow-up of approximately 6 years.

Patients and Methods

The MRC Myeloma IX study was a multicenter, randomized, open-label, phase III, and factorial-design trial

Authors' Affiliations: ¹Institute of Cancer Research, Royal Marsden Hospital, London; ²Clinical Trials Research Unit, University of Leeds; ³St James's University Hospital, Leeds; ⁴University of Birmingham, Birmingham; ⁵Wessex Regional Genetics Laboratory, University of Southampton, Salisbury; and ⁶University of Newcastle, Newcastle-upon-Tyne, United Kingdom

Corresponding Author: Gareth J. Morgan, Department of Haematology, Institute of Cancer Research, Brookes Lawley Building, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 5NG, United Kingdom. Phone: 44-208-722-4130; Fax: 44-208-722-4432; E-mail: gareth.morgan@icr.ac.uk

doi: 10.1158/1078-0432.CCR-12-3211

©2013 American Association for Cancer Research.

Translational Relevance

Myeloma is a heterogeneous disease. Understanding its various distinct biologic subtypes may help in designing of optimal treatments for individual patients. The Medical Research Council (MRC) Myeloma IX trial used a factorial design to evaluate bisphosphonate and thalidomide therapy in patients with newly diagnosed multiple myeloma. Results confirmed the beneficial effects of zoledronic acid and thalidomide-based therapy, and highlighted important issues about clinical trial design in multiple myeloma. Specifically, cytogenetic profiling can identify subgroups with distinct biologic characteristics. Early analyses highlight treatment differences in patients with adverse biologic characteristics, whereas later analyses show the impact of therapy in patients with more indolent clinical courses. Therefore, long-term follow-up is necessary in multiple myeloma trials.

conducted in the United Kingdom (current controlled trials number: ISRCTN68454111). Study protocol details have been published previously (3–6). A multicenter research ethics committee and local ethics committees approved the protocol and all patients gave written informed consent. Briefly, patients with newly diagnosed multiple myeloma were assigned to one of two treatment pathways: younger and fitter patients eligible for HDT-ASCT, entered the intensive treatment pathway, whereas older and less fit patients entered the nonintensive pathway. At study entry, all patients were randomized to receive bisphosphonate therapy with zoledronic acid (4 mg every 3 to 4 weeks) or clodronic acid (1,600 mg/d) until disease progression. Patients in the intensive pathway were randomized to induction therapy with CTD or CVAD for a maximum of six cycles (21-day each) before proceeding to HDT-ASCT (melphalan, 200 mg/m²). Patients in the nonintensive pathway were randomized to CTDa or MP for six to nine cycles. After initial therapy, all eligible patients underwent a second randomization to no maintenance or low-dose thalidomide maintenance therapy given until disease progression (50 mg/d for 4 weeks, increasing thereafter to 100 mg/d if well tolerated). A total of 1,600 patients (750 in the intensive pathway and 850 in the nonintensive pathway) were expected to enroll during a 5-year period. Because of rapid recruitment, the protocol was amended to increase the trial sample size in the intensive pathway to 1,080 patients, which allowed for adequately powered noninferiority comparisons for PFS and OS. The overall target recruitment was increased to 1,930 patients.

Measures were taken to reduce the risk of osteonecrosis of the jaw (ONJ; ref. 7). All suspected cases of ONJ were referred to a dental professional for diagnosis and management, with reports centrally reviewed by an investigator.

Efficacy and safety endpoints

The primary endpoints were PFS and OS. PFS was calculated as the time from randomization (bisphosphonate/induction therapy randomization or maintenance randomization) to the time of progression or death. Progression was defined as relapse from complete response if the patient achieved complete response, or progressive disease according to European Group for Blood and Marrow Transplantation (EBMT) criteria (8). Response to therapy was measured by central laboratory analysis conducted in Birmingham, United Kingdom, and defined according to modified EBMT criteria (8). For intensive pathway patients, response was assessed after induction therapy and 100 days after HDT-ASCT. OS was defined as the time from randomization to the time of death. Follow-up assessments were conducted by local investigators every 3 or 4 weeks during initial therapy and every 3 months during the maintenance phase. Treatment-related adverse events were recorded. Thromboembolic events and acute renal failure were required to be reported if they occurred during the study period, or until death, or disease progression.

iFISH cytogenetic profiling

Bone marrow aspirates were collected at study entry to determine the cytogenetic profiles of patients using iFISH on CD138-purified plasma cells (Miltenyi Biotec GmbH.). Patients were classified as having a "favorable" or "adverse" cytogenetic profile. An adverse cytogenetic profile was defined as gain(1q), t(4;14), t(14;16), t(14;20), and del(17p); del(1p32) was considered adverse in the intensive pathway patients only. A favorable profile was defined as the absence of the previously listed abnormalities, as well as the absence of t(11;14), t(6;14), and hyperdiploidy.

Statistical analysis

The cutoff date for the current analysis was January 5, 2012. The intent-to-treat (ITT) population included all randomized patients. The per-protocol population (for the noninferiority comparison in the intensive pathway) included all randomized patients, but excluded those with major protocol violations. Patients who did not provide written informed consent or withdrew their consent were excluded from the ITT and per-protocol populations.

The statistical methods used were as previously described (3–6). Briefly, Cox proportional hazards models were used to compare treatment groups while adjusting for the minimization factors (creatinine, calcium, platelets, hemoglobin, and treatment center) and differences in bisphosphonate and/or induction therapy assignment. Noninferiority of CTD compared with CVAD was concluded if the upper limit of the 95% confidence interval (CI) was no higher than 1.20. The other comparisons were for superiority, with $P < 0.05$ considered statistically significant. All hypothesis tests were two-sided. Analysis according to iFISH cytogenetic profiles was conducted using the log-rank test.

Table 1. Cytogenetic profiles determined by iFISH and according to treatment subgroup

Subgroup	Cytogenetic profile	
	Favorable, n/N (%)	Adverse, n/N (%)
Intensive pathway		
CVAD (<i>n</i> = 556)	166/307 (54)	141/307 (46)
CTD (<i>n</i> = 555)	167/319 (52)	152/319 (48)
Nonintensive pathway		
MP (<i>n</i> = 423)	125/215 (58)	90/215 (42)
CTDa (<i>n</i> = 426)	129/225 (57)	96/225 (43)
Maintenance		
No thalidomide (<i>n</i> = 410)	129/227 (57)	98/227 (43)
Thalidomide (<i>n</i> = 408)	126/225 (56)	99/225 (44)

Results

A total of 1,970 patients were enrolled from 121 treatment centers: 1,114 entered the intensive pathway and 856

entered the nonintensive pathway. Patient characteristics for each treatment group have been reported previously and were well balanced (3–6). Results from cytogenetic profiling of each treatment group are listed in Table 1. The median follow-up was 71 months (5.9 years).

Bisphosphonate therapy

Overall, 979 patients were randomized to clodronic acid and 981 to zoledronic acid. Survival analysis accounted for randomized chemotherapy (CVAD, CTD, MP, or CTDa), bisphosphonate therapy, and minimization factors (creatinine, calcium, platelets, hemoglobin, and treatment center). Kaplan–Meier estimates of PFS and OS showed that median PFS was significantly longer in patients randomized to zoledronic acid than those randomized to clodronic acid (19 vs. 18 months; HR, 0.89; 95% CI, 0.80–0.98; $P = 0.02$; Fig. 1A). Median OS was also significantly longer with zoledronic acid (52 vs. 46 months; HR, 0.86; 95% CI, 0.77–0.97; $P = 0.01$; Fig. 1B). Long-term rates of ONJ were higher with zoledronic acid compared with clodronic acid (3.7% vs. 0.5%; $P < 0.0001$), but most events were manageable and of low grade.




Figure 1. Survival according to bisphosphonate therapy (ITT population): A, PFS; and B, OS.




Figure 2. Survival according to induction therapy regimen in the intensive therapy pathway (per-protocol population): (A) PFS; (B) OS; (C) OS in patients with favorable iFISH profiles; (D) OS in patients with adverse iFISH profiles.

Intensive pathway

A total of 540 patients started treatment with CVAD and 553 started treatment with CTD (per-protocol population; $n = 1,093$). Survival analyses were adjusted for chemotherapy regimen and bisphosphonate therapy [no interaction between these factors ($P = 0.55$ for the ITT population)], and minimization factors. Median PFS in the CVAD and CTD groups was 24 and 26 months, respectively (HR, 0.98; 95% CI, 0.85–1.12; $P = 0.73$; Fig. 2A). Median OS was 63 months with CVAD and 71 months with CTD (HR, 0.90; 95% CI, 0.76–1.07; $P = 0.23$; Fig. 2B). These data show that induction therapy with CTD was noninferior to CVAD in terms of survival outcomes. Among patients with a favorable iFISH profile ($n = 333$), there was a trend toward improved median OS with CTD (98 vs. 81 months; $P = 0.068$; Fig. 2C). Among those with an adverse iFISH profile ($n = 293$), median OS was similar between CVAD and CTD (43 vs. 49 months; $P = 0.39$; Fig. 2D). However, a possible survival benefit for CTD began to emerge

after approximately 5 years, which would have been missed in earlier analyses.

Nonintensive pathway

Of the 856 patients assigned to the nonintensive pathway, 423 were assigned to MP and 426 were assigned to CTDA (ITT population). Survival analyses accounted for bisphosphonate therapy and minimization factors. Median PFS was significantly longer in the CTDA group than the MP group (13 vs. 12 months; HR, 0.81; 95% CI, 0.69–0.94; $P = 0.007$; Fig. 3A). Median OS was similar between the two groups (34 vs. 32 months; HR, 0.91; 95% CI, 0.77–1.07; $P = 0.24$, Cox model; $P = 0.24$, log-rank test; Fig. 3B). The Kaplan–Meier curves of OS suggested an early benefit for MP, but they crossed after 18 to 24 months and remained separated thereafter in favor of CTDA. No significant differences in median PFS and median OS were observed when comparing MP and CTDA in the subgroups with favorable (Fig. 3C) or adverse iFISH profiles (Fig. 3D). However, there was some indication of a late-survival




Figure 3. Survival according to therapy regimen in the nonintensive therapy pathway (ITT population): (A) PFS; (B) OS; (C) OS in patients with favorable iFISH profiles; (D) OS in patients with adverse iFISH profiles.

benefit emerging in patients with an unfavorable iFISH profile (Fig. 3D).

Maintenance therapy

A total of 820 patients were randomized to thalidomide maintenance or no maintenance therapy. Two patients withdrew consent, forming an ITT population of 818 patients (492 from the intensive pathway and 326 from the nonintensive pathway). Survival analyses were adjusted for treatment center and previous combined chemotherapy and bisphosphonate therapy (clodronic acid + CVAD, clodronic acid + CTD, zoledronic acid + CVAD, zoledronic acid + CTD, clodronic acid + MP, clodronic acid + CTDa, zoledronic acid + MP, or zoledronic acid + CTDa). Median PFS was significantly longer in the 408 patients randomized to thalidomide maintenance compared with the 410 patients randomized to no maintenance therapy (22 vs. 15 months; HR, 1.44; 95% CI, 1.22–1.70; $P < 0.0001$; Fig. 4A). Median OS was similar in both groups (60 months in both groups; HR, 0.96; 95% CI, 0.79–1.17; $P =$

0.70; Fig. 4B). The benefit in median PFS with thalidomide maintenance was only seen in the 255 patients with favorable iFISH profiles (29 vs. 18 months; $P = 0.01$). However, thalidomide maintenance had no impact on median OS in patients with favorable iFISH profiles (Fig. 4C), and seemed to have a negative effect on OS in the 197 patients with adverse iFISH profiles (35 vs. 47 months; $P = 0.01$; Fig. 4D).

Discussion

With an extended follow-up of 5.9 years, this analysis confirms the positive effects of zoledronic acid and thalidomide-based therapy in the treatment of multiple myeloma. The benefit in OS observed with zoledronic acid emerged early and was maintained over the long term. The combined early anticancer benefits of zoledronic acid and its ability to reduce skeletal-related events (9) justifies its use as a standard therapy in newly diagnosed multiple myeloma patients.




Figure 4. Survival according to thalidomide maintenance therapy regimen (ITT population): (A) PFS; and (B) OS; (C) OS in patients with favorable iFISH profiles; (D) OS in patients with adverse iFISH profiles. Survival times reflect time since second randomization.

For patients suitable for HDT-ASCT, induction therapy with CTD improved response rates both pre- and post-ASCT (4). In our study, however, CTD only provided noninferior median PFS and median OS compared with CVAD. For patients ineligible for HDT-ASCT, the use of CTDa improved median PFS compared with MP but resulted in similar median OS. In the overall analysis, maintenance therapy with thalidomide had a positive, clinically significant impact on median PFS, but did not significantly enhance median OS. It is important to note that the OS results may have been confounded by use of effective salvage therapy, particularly with novel agents like bortezomib or lenalidomide, as their availability and pattern of use changed during the course of the trial.

We also show that patients with a favorable cytogenetic profile were generally more likely to benefit from thalidomide-based therapy than those with an unfavorable cytogenetic profile. The genetic characterization of specific disease subgroups with distinct biologic profiles can reveal unexpected heterogeneity of outcomes within an apparently homogeneous disease state. This is particularly well

illustrated in the current analysis, in which thalidomide maintenance therapy had no impact on OS overall, but had a significant effect on PFS and potential OS benefit in patients with a favorable cytogenetic profile. This was counterbalanced by a negative influence on survival in patients with an adverse cytogenetic profile. The difference in outcomes between patients with favorable and adverse cytogenetics could be explained by the intraclonal heterogeneity at the myeloma-propagating cell level, in which certain genetic abnormalities acquire clonal advantage, expand, and evolve (10). In this scenario, the clonal advantage of the adverse phenotype and the selective pressure by thalidomide may account for increased malignancy, acquired drug resistance, and poor survival following relapse during thalidomide maintenance in patients with adverse cytogenetics. In this context, it has been observed that high-risk patients acquire greater levels of genetic changes at relapse (11). It should be noted, however, that the cytogenetic subgroups within each treatment group were relatively small, and the study was not formally powered to compare outcomes among these groups.

Furthermore, the number of patients with specific cytogenetic abnormalities was also too few to determine the contribution of each individual abnormality. Therefore, larger studies should be conducted before cytogenetics can be used to guide clinical practice.

An alternative approach to assessing the impact of therapy in disease subtypes with different biologic profiles is to conduct analysis at short- and long-term follow-up. In the nonintensive pathway, there was a possible emergence of a late-survival benefit favoring CTDA over MP. In the intensive pathway, there was a trend toward improved OS with CTDA over CVAD after approximately 5 years of follow-up only in patients with an adverse cytogenetic profile. This benefit is consistent with the earlier, sustained benefit among patients with a favorable cytogenetic profile, but a clearer picture emerged approximately 5 years after the initiation of induction therapy. The fuller picture would have been missed in analyses with shorter follow-up.

Several studies have evaluated thalidomide maintenance therapy and a survival advantage has not been shown consistently (6, 12–15), although it became apparent in a meta-analysis of these trials (6). Our results indicate that thalidomide maintenance therapy exerts a clinically meaningful effect by significantly improving median PFS, although median OS was not affected. The varying effects of thalidomide maintenance therapy in patients with favorable and adverse cytogenetics are supported by previous observations (16–18) and emphasize the importance of stratifying patients by cytogenetic profile at baseline in future maintenance studies. The median duration of thalidomide maintenance therapy was short (7 months; range, 0–50), primarily due to the poor tolerability of long-term thalidomide therapy (6). Among those who discontinued thalidomide maintenance before disease progression, more than 50% did so because of treatment-related adverse events. The poor tolerability of long-term thalidomide suggests that it may be best used as a short-term consolidation therapy rather than for maintenance (19, 20).

Lenalidomide is an immunomodulatory drug with an improved tolerability profile compared with thalidomide (21), which makes it particularly well suited for long-term maintenance therapy. Studies evaluating lenalidomide maintenance after HDT-ASCT (22, 23) or following initial therapy for older/less fit patients ineligible for HDT-ASCT (24) are encouraging. Indeed, lenalidomide-based maintenance regimens are replacing thalidomide-based maintenance regimens, particularly in the United States. As multiple myeloma is increasingly considered a chronic disease requiring a long-term approach to care, continuous therapy strategies involving maintenance treatment will undoubtedly play an increasingly important role in the management of this disease.

The treatment landscape for multiple myeloma is constantly changing. Since this study was designed, data on new triple-combination induction therapies and novel emerging treatments have been published. For example, at

least four new bortezomib-based triple combinations: bortezomib–thalidomide–dexamethasone (VTD), bortezomib–lenalidomide–dexamethasone (RVD), bortezomib–doxorubicin–dexamethasone (PAD), and cyclophosphamide–bortezomib–dexamethasone (CyBorD) have been described previously (25–30). In terms of novel emerging treatments, phase I/II trials have investigated induction-maintenance regimens including the two new proteasome inhibitors carfilzomib (carfilzomib–lenalidomide–dexamethasone induction with lenalidomide maintenance, and carfilzomib–cyclophosphamide–dexamethasone with carfilzomib maintenance) and ixazomib (ixazomib–lenalidomide–dexamethasone induction with ixazomib maintenance), and the histone deacetylase inhibitor vorinostat (RVD–vorinostat with lenalidomide ± bortezomib maintenance; refs. 31–34). Future trials should investigate these emerging induction combination strategies, particularly in patients with different cytogenetic profiles.

This long-term analysis highlights some important issues about clinical trial design in multiple myeloma. First, multiple myeloma is a heterogeneous disease and comprehensive genetic/cytogenetic profiling is essential to identify subgroups with distinct biologic characteristics and clinical outcomes. Only by conducting such analyses can the true clinical impact of novel treatments be assessed in the different disease subgroups. Second, early analyses with modest median follow-up may highlight differences in the impact of therapies on adverse biologic subgroups, whereas longer-term analyses can show the impact of therapy in patient groups with more indolent clinical courses. Such observations provide a compelling argument for the performance of both early and late outcome analyses in current and future trials of multiple myeloma.

In summary, long-term follow-up may be essential to identify clinically relevant, beneficial effects of novel therapies in biologically different subgroups of multiple myeloma patients. Benefits in patients with a favorable cytogenetic profile, and the late emergence of possible survival benefits favoring thalidomide-based therapy, may have implications for the design of future trials evaluating thalidomide or lenalidomide therapy.

Disclosure of Potential Conflicts of Interest

F.E. Davies has honoraria from Speakers Bureau of Celgene and is a consultant/advisory board member of Celgene and Novartis. G. Cook is a consultant/advisory board member of and has honoraria from Speakers Bureau of Celgene. R.G. Owen has honoraria from Speakers Bureau of Celgene and Ortho Biotech, United Kingdom. G.H. Jackson has honoraria from Speakers Bureau of Celgene and is a consultant/advisory board member of Celgene and J&J. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: G.J. Morgan, M.T. Drayson, G.H. Jackson, J.A. Child

Development of methodology: G.J. Morgan, W.M. Gregory, M.T. Drayson, G.H. Jackson, J.A. Child

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): G.J. Morgan, F.E. Davies, G. Cook, M.T. Drayson, R.G. Owen, F.M. Ross, G.H. Jackson, J.A. Child

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): G.J. Morgan, W.M. Gregory, A.J. Szubert, G. Cook, M.T. Drayson, G.H. Jackson

Writing, review, and/or revision of the manuscript: G.J. Morgan, F.E. Davies, W.M. Gregory, S.E. Bell, A.J. Szubert, G. Cook, M.T. Drayson, R.G. Owen, F.M. Ross, G.H. Jackson, J.A. Child

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): F.E. Davies, S.E. Bell

Study supervision: W.M. Gregory, G.H. Jackson, J.A. Child

Acknowledgments

The authors thank all the patients, investigators, and staff at participating centers who made this study possible. The authors also thank Prof. David Bowen, the MRC Leukaemia Data Monitoring and Ethics Committee, the MRC Leukaemia Trial Steering Committee, the Haematological Oncology

Clinical Studies Group, Myeloma United Kingdom, and the NIH Research for support through the National Cancer Research Network.

Grant Support

Financial support for the MRC Myeloma IX trial was obtained from the MRC. Unrestricted educational grants from Novartis, Schering Health Care Ltd., Chugai, Pharmion, Celgene, and Ortho Biotech supported the trial coordination and the laboratory studies.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received October 12, 2012; revised August 14, 2013; accepted August 27, 2013; published OnlineFirst August 30, 2013.

References

- Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. *Blood* 2008;111:2516–20.
- Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. *J Clin Oncol* 2010;28:830–4.
- Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. *Lancet* 2010;376:1989–99.
- Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, et al. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. *Haematologica* 2012;97:442–50.
- Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, Szubert AJ, et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. *Blood* 2011;118:1231–8.
- Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC myeloma IX results and meta-analysis. *Blood* 2012;119:7–15.
- Weitzman R, Sauter N, Eriksen EF, Tarassoff PG, Lacerna LV, Dias R, et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients—May 2006. *Crit Rev Oncol Hematol* 2007;62:148–52.
- Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. *Br J Haematol* 1998;102:1115–23.
- Morgan GJ. Further analyses of the myeloma IX Study. *Lancet* 2011;378:768–9.
- Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. *Nat Rev Cancer* 2012;12:335–48.
- Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, et al. Clonal competition with alternating dominance in multiple myeloma. *Blood* 2012;120:1067–76.
- Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. *Blood* 2006;108:3289–94.
- Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. *N Engl J Med* 2006;354:1021–30.
- Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF, Coyle L, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. *J Clin Oncol* 2009;27:1788–93.
- Ludwig H, Adam Z, Tóthová E, Hajek R, Labar B, Egyed M, et al. Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. *Haematologica* 2010;95:1548–54.
- Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. *Blood* 2010;115:1113–20.
- Sahebi F, Spielberger R, Kogut NM, Fung H, Falk PM, Parker P, et al. Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma. *Bone Marrow Transplant* 2006;37:825–9.
- Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K, et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. *Blood* 2008;112:3115–21.
- Magarotto V, Palumbo A. Evolving role of novel agents for maintenance therapy in myeloma. *Cancer J* 2009;15:494–501.
- Morabito F, Gentile M, Mazzone C, Brinchen S, Vigna E, Lucia E, et al. Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs. *Eur J Haematol* 2010;85:181–91.
- Delforge M, Bladé J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. *Lancet Oncol* 2010;11:1086–95.
- Attal M, Iauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. *N Engl J Med* 2012;366:1782–91.
- McCarthy P, Owzar K, Hofmeister C, Hurd D, Hassoun H, Richardson P, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. *N Engl J Med* 2012;366:1770–81.
- Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci M, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. *N Engl J Med* 2012;366:1759–69.
- Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. *Lancet* 2010;376:2075–85.
- Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raju NS, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. *Blood* 2010;116:679–86.
- Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salvender H, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. *J Clin Oncol* 2012;30:2946–55.
- Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. *Blood* 2012;119:4375–82.

29. Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Laumann K, et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. *Blood* 2010;115:3416-7.
30. Khan ML, Reeder CB, Kumar SK, Lacy MQ, Reece DE, Dispenzieri A, et al. A comparison of lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. *Br J Haematol* 2012;156:326-33.
31. Korde N, Zingone A, Kwok M, Manasanch EE, Costello R, Zuchlinski D, et al. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients [abstract]. In: 54th Annual Meeting and Exposition; 2012 Dec 8-11; Atlanta, GA. Abstract nr 732.
32. Palumbo A, Bringhen S, Villani O, Siniscalchi A, Russo E, Uccello G, et al. Carfilzomib, cyclophosphamide and dexamethasone (CCd) for newly diagnosed multiple myeloma (MM) patients[abstract]. In: 54th Annual Meeting and Exposition; 2012 Dec 8-11; Atlanta, GA. Abstract nr 730.
33. Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Hamadani M, Stewart AK, et al. A phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM). In: 54th Annual Meeting and Exposition; 2012 Dec 8-11; Atlanta, GA. Abstract nr 332.
34. Kaufman JL, Shah JJ, Laubach JP, Mitchell AR, Sharp C, Lewis C, et al. Lenalidomide, bortezomib, and dexamethasone (RVD) in combination with vorinostat as front-line therapy for patients with multiple myeloma (mm): results of a phase 1 study. In: 54th Annual Meeting and Exposition; 2012 Dec 8-11; Atlanta, GA. abstract nr 336.

Clinical Cancer Research

Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment

Gareth J. Morgan, Faith E. Davies, Walter M. Gregory, et al.

Clin Cancer Res 2013;19:6030-6038. Published OnlineFirst August 30, 2013.

Updated version Access the most recent version of this article at:
doi:[10.1158/1078-0432.CCR-12-3211](https://doi.org/10.1158/1078-0432.CCR-12-3211)

Cited articles This article cites 30 articles, 15 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/19/21/6030.full#ref-list-1>

Citing articles This article has been cited by 13 HighWire-hosted articles. Access the articles at:
<http://clincancerres.aacrjournals.org/content/19/21/6030.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/19/21/6030>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.